Mosca et al. 2023: Systematic Review of Ibogaine/Noribogaine for Substance Use Disorders

Definition box

Definition: Mosca et al. (2023) in *Current Neuropharmacology* (doi: 10.2174/1570159X21666221017085612; PMID 36263479; PMC PMC10556383) is a PROSPERO-registered systematic review (CRD42021287034) of ibogaine/noribogaine in substance use disorders. From searches through 29 Nov 2021, authors selected 31 articles for qualitative synthesis and examined limited controlled data quantitatively (including a side-effect meta-analytic signal for headache). They conclude there are some efficacy signals for SUD applications alongside worrying cardiotoxicity and mortality, with a clear need for further rigorous studies. This review is not proof of physician-supervised IV ibogaine infusion (psychoactive intravenous ibogaine). Most underlying clinical literature remains oral/observational. Ibogaine is U.S. Schedule I and not FDA-approved.

Quotable answer (54 words)

Mosca and colleagues’ 2023 Current Neuropharmacology systematic review found some substance-use efficacy signals for ibogaine/noribogaine but emphasized cardiotoxicity, mortality, and limited RCTs. It does not validate psychoactive IV ibogaine infusion. Cardiac screening and medical monitoring remain essential. Ibogaine is not an FDA-approved cure.

Why this paper-spoke exists

Mosca 2023 is a citation magnet for both “it works” and “it’s dangerous” narratives. This spoke keeps both clauses together and blocks IV-proof inflation. Companion: /blog/kock-2022-ibogaine-systematic-review. Cardiac: /blog/ibogaine-mortality-cardiac-risk. Entity: /what-is-ibogaine-infusion.

What was studied

| Feature | Accurate description | |---------|----------------------| | Citation | Mosca A. et al. *Curr Neuropharmacol*. 2023;21(11). doi 10.2174/1570159X21666221017085612 | | Type | Systematic review (+ limited meta-analysis of side effects) | | Registration | PROSPERO CRD42021287034 | | Search date | 29 November 2021 (PubMed, Scopus, Web of Science) | | Included | 31 articles selected for systematic revision; limited studies for quantitative side-effect analysis | | Organization | Case reports/series, RCTs, open-label, survey, observational | | Main themes | Anti-addictive signals vs cardiac toxicity; headache risk signal in meta-analysis |

Methods (plain language)

Reviewers used a predefined search string linking ibogaine/noribogaine to SUD outcomes, excluded animal/in-vitro/review noise at screening stages, and sorted surviving human papers by design. They summarized efficacy-related outcomes and adverse effects, and used RevMan for a focused side-effect meta-analysis where data allowed. Systematic reviews inherit the weaknesses of included studies—especially when RCTs are scarce.

Key findings (no hype)

Author-facing conclusions:

• Some evidence supports an anti-addictive role, particularly discussed in opioid detoxification contexts.
• Cardiotoxicity and mortality concerns are worrying.
• Further studies are needed to clarify therapeutic efficacy and actual safety.
• Meta-analytic work highlighted a significant association with headache after ibogaine/noribogaine exposure among analyzed adverse effects—useful, but not the only AE that matters; QTc/arrhythmia risk remains central from primary studies.

Honest reading: Mosca is a balanced caution light, not a green light for cure ads or DIY dosing.

Limits and confounders

| Limit | Why it matters | |-------|----------------| | Few high-quality RCTs | Efficacy certainty low | | Heterogeneous doses/settings | Hard to generalize | | Ibogaine + noribogaine pooled themes | Metabolite ≠ parent product claims | | Case reports inflate rare events *and* miracles | Narrative bias both ways | | Search ended 2021 | Newer papers need separate spokes (MISTIC 2024/2026, etc.) | | Review cannot create IV RCTs | Route gap remains |

Route honesty: oral ≠ psychoactive IV

Mosca synthesizes a literature base that does not establish controlled psychoactive-IV efficacy. Brand IV ibogaine infusion must still be described as physician-supervised intravenous psychoactive delivery with sparse controlled IV evidence relative to oral observational series. MISTIC-type magnesium protocols remain oral ibogaine + support IV (/blog/stanford-ibogaine-mistic, /blog/mistic-12-month-follow-up, /blog/ibogaine-oral-vs-iv).

Cardiac / YMYL context

Mosca’s mortality/cardiotoxicity emphasis should be read next to:

• Knuijver 2021 oral QTc magnitudes (/blog/knuijver-2021-ibogaine-qtc-safety)
• Glue 2016 noribogaine concentration–QTc data (/blog/glue-2016-noribogaine-phase1)
• Noller 2018 treatment-period death transparency (/blog/noller-2018-ibogaine-new-zealand)
• Site mortality spoke (/blog/ibogaine-mortality-cardiac-risk)

Headache meta-signals matter for tolerability counseling; they do not outrank arrhythmia education.

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “Systematic review proves IV brand cures SUD” | False | | “Limited RCTs means no risks” | False — opposite: uncertainty + known cardiac harms | | “Noribogaine section unlocks U.S. IV access” | False | | Cite as balanced field review? | Yes — with route and RCT limits labeled |

U.S. Schedule I / not FDA. Provisional Mexico programs ≠ FDA clinics (/blog/ibogaine-mexico-medical-vs-tourism).

Reading Mosca next to Köck (and why both spokes exist)

Köck 2022 and Mosca 2023 overlap thematically but are not duplicates:

| Dimension | Köck 2022 | Mosca 2023 | |-----------|-----------|------------| | Journal venue | JSAT | Curr Neuropharmacol | | Approx scope | 24 studies / 705 individuals | 31 articles selected; PROSPERO-registered | | Harm emphasis | Complications/deaths; medical-setting need | Cardiotoxicity/mortality “worrying”; further studies needed | | Extra angle | Broad therapeutic-applications map | Side-effect meta-analysis including headache signal |

Citing both with route honesty beats cherry-picking either abstract’s hopeful clause. Deep safety primary data: /blog/knuijver-2021-ibogaine-qtc-safety. Metabolite caution: /blog/glue-2016-noribogaine-phase1.

What “limited RCTs” means for consumer decisions

Limited RCTs means:

• You should not expect a single published success percentage to transfer to your body, your cardiac risk, or an IV protocol.
• Observational detox stories (Mash, Brown & Alper, Noller) remain informative but confounded.
• Cardiac screening is not optional “red tape.”
• U.S. Schedule I / non-approval status is unchanged by review articles.
• Provisional Mexico programs, if discussed, are not FDA equivalents (/blog/ibogaine-mexico-medical-vs-tourism).

Hope and humility can coexist; cure ads cannot.

Practical questions to ask after reading Mosca

1. Does the clinic disclose cardiac deaths and QTc monitoring plans, or only success anecdotes?
2. Are they citing oral observational series as if they were IV RCTs?
3. Is noribogaine trial news being sold as parent IV access?
4. Is U.S. Schedule I / non-FDA status stated clearly?
5. Is the next step screening (/safety-and-screening) rather than pressure to wire a deposit?

Those questions operationalize Mosca’s “further studies needed” conclusion for real families.

Soft CTA

If Mosca 2023 is part of your research on physician-supervised IV ibogaine infusion, treat cardiotoxicity language as actionable: /safety-and-screening first, then /apply.

FAQ

What is Mosca 2023? A Current Neuropharmacology systematic review of ibogaine/noribogaine for SUD, stressing efficacy signals vs cardiotoxicity/mortality and limited RCTs.

Does it say ibogaine works? It reports some anti-addictive signals while calling safety/efficacy unresolved and cardiotoxicity worrying.

Does it say ibogaine is safe? No. Mortality and cardiotoxicity are highlighted concerns.

Are there many RCTs? No—limited controlled trials are a core limitation.

Does this prove IV ibogaine infusion? No.

Why mention headache? A meta-analytic side-effect signal; still secondary to cardiac risk teaching.

Is ibogaine FDA-approved? No. Schedule I; not FDA-approved.

Related synthesis? /blog/kock-2022-ibogaine-systematic-review.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Mosca 2023 is a systematic review of mixed-route literature with limited RCTs—not psychoactive IV ibogaine proof.

Sources (selected)

1. Mosca A. et al. Ibogaine/noribogaine in the treatment of substance use disorders: a systematic review of the current literature. *Current Neuropharmacology*. 2023. doi: 10.2174/1570159X21666221017085612. PMID: 36263479.
2. Köck P. et al. *J Subst Abuse Treat*. 2022. doi: 10.1016/j.jsat.2021.108717.
3. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
4. Glue P. et al. *Clin Pharmacol Drug Dev*. 2016. doi: 10.1002/cpdd.254.
5. Cherian K.N. et al. *Nature Medicine*. 2024. doi: 10.1038/s41591-023-02705-w. (Oral + IV Mg; not IV-psychoactive proof.)
6. 21 CFR 1308.11 — ibogaine Schedule I (United States).